TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02308280

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib following nonmyeloablative allogeneic transplant
Description: Bortezomib 1,3 mg/m2 subcutaneously every 2 weeks for 1 year (26 injections) starting on day +120 from a non myeloablative sibling or 10/10 unrelated allogeneic transplantation
Study: NCT00673270

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Description: 50 mg of intravenous hydrocortisone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of Fludrocortisone
Description: Tablet of placebo of Fludrocortisone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of Fludrocortisone
Description: Tablet of placebo of Fludrocortisone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of Hydrocortisone
Description: 2 ml of isotonic saline solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of Hydrocortisone
Description: 2 ml of isotonic saline solution
Study: NCT03828370

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: B-SMART Intervention Group
Description: The B-SMART mobile web app will contain four modules: 1) Supporting Abstinence, 2) Shared Positive Activities, 3) Common Challenges for Family Members with IID, and 4) Effective Communication. Within each module there will be a series of learning activities, including presentation text, interactive engagement, and videos. All app content will be available in both English and Spanish, based on user language preference.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual and Customary Information Group
Description: Participants randomized to the usual and customary care (UC) group will receive a website with a pamphlet on the IID installed in their vehicle and the manufacturer information provided about the IID in PDF format, in both English and Spanish. This constitutes a UC group, as such pamphlets are widely available to DWI offenders who have IIDs installed in their vehicles. Thus, providing this pamphlet represents a standard information provision for first-time DWI offenders and their CFMs.
Study: NCT00976118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: masitinib (AB1010)
Description: oral masitinib 3 or 6 mg/kg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: matching placebo to masitinib
Study: NCT02596750

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Microneedle Roller
Description: 200 micrometer length microneedles (MR2 roller, Clinical Resolution Laboratories, Inc.) mounted on a disposable roller

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham microneedle Roller
Description: Flat roller without microneedles
Study: NCT04127812

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Savor the Flavor
Description: A series of five interactive classroom lessons focused on mindfulness in eating.
Study: NCT01142128

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nexium (esomeprazole magnesium)
Description: one 40 mg capsule per day for one month

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to Nexium
Description: one capsule per day for one month

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Viokase 16 (pancrelipase) + Nexium
Description: Viokase 16 (pancrelipase) + Nexium capsules are given per day for one month with the addition of esomeprazole magnesium, one 40mg capsule per day for one month

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Viokase 16 + placebo to Nexium
Description: Viokase 16 pancrelipase tablets are given per day for one month with one capsule of placebo to esomeprazole magnesium, one per day for one month
Study: NCT00761748

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Convatec Uro 2-piece
Description: Specific name of the device: 'Combihesive Natura® with a Durahesive Convex-It® base plate, 45 mm coupling, moldable (13-22 and 22-33 mm) hole size with boarder tape'.~The subjects are asked to test each of the two products for 21 days plus/minus 3 days in a randomised order and in accordance with their normal frequency of change and normal use pattern. The duration of the clinical investigation should be enough time to identify any difference in user-preference. If the subject is in the middle of testing an urostomy base plate when the test period is turning into the next period, the urostomy base plate can be worn until it needs to be changed. It is not possible to blind the investigation as the appearance of the test- and refer-ence products are very different in the look.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SenSura Uro 2-piece
Description: SenSura URO 2-piece Extended Wear, convex light, 50 mm coupling, cuttable (15-33 mm)
Study: NCT03745430

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: 8 mg/kg (days 1 and 15, q4w) until disease progression
Study: NCT03821701

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entresto
Description: Sacubitril Valsartan Sodium Tablets, 100mg bid, among whole study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entresto
Description: Sacubitril Valsartan Sodium Tablets, 100mg bid, among whole study

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ACEI/ARB
Description: Choose one of ACEI/ARB according to the clinical condition among the whole study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ACEI/ARB
Description: Choose one of ACEI/ARB according to the clinical condition among the whole study.
Study: NCT02709226

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Radiation therapy will be administered daily Monday-Friday at NCI, ROB unless the treatment schedule requires amendment in the event of inclement weather or federal holidays. Radiation therapy dose will be administered as per on consecutive treatment days, 5 fractions per week via a linear accelerator using 6 MV photons or greater. Dose escalation is as follows: dose level 1 (DL1) 3.5 Gy x 10; dose level 2 (DL2) 3.5 Gy x 12; dose level 3 (DL3) 3.5 Gy x 14. If 2 DLTs are observed in the second dose level a step down dose of 3.0 Gy x 14 fractions will be tested. If 2 DLTs are observed in the third dose level a step down dose of 3.0 Gy x 17 fractions will be tested. The study will have 3 planned re-irradiation dose levels, with 1 to 6 patients per dose level using the 3+3 design to define the MTD. The number of patients may be increased to 9 total patients at the MTD ( provided no DLT) with a maximum of 21 evaluable patients enrolled.
Study: NCT02593032

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pre-filled trays
Description: Randomized Control Trial Patients in the research treatment group receive pre-filled, 3x7 disposable trays that separate their medication by dose and time (e.g. morning, afternoon, evening). These pre-filled trays are inserted into a connected, weekly pillbox that detects when pills are removed from its wells.
Study: NCT04028115

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: Scheduled visits: Patients included in the trial will be treated with Ixazomib 4 mg on day 1, 8, and 15 in a 28-day cycle for up to 24 cycles. Patients will be evaluated every 4th week by a medical doctor, prior to initiation of a new cycle of Ixazomib.
Study: NCT00585559

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos for acetaminophen and N-acetylcysteine
Description: Placebos for acetaminophen and N-acetylcysteine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: APAP 1 gm every 6 hours and N-acetylcysteine placebo
Description: Acetaminophen 1 gm every 6 hours and N-acetylcysteine placebo
Study: NCT00611130

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vigabatrin
Description: Tablets twice a day for 9 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: tablets twice daily for 9 weeks
Study: NCT02227212

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glargine U300 (new formulation of insulin glargine) HOE901
Description: Pharmaceutical form:solution for injection Route of administration: subcutaneous
Study: NCT01938222

Intervention type: PROCEDURE
Intervention: Short Stitch
Description: MonoMax® suture material USP (United States Pharmacopeia) 2/0, 150 cm, HR (half-round) 26 mm needle, will be applied in the short stitch technique (6:1) for abdominal wall closure.
Study: NCT04007029

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Chimeric Antigen Receptor T-Cell Therapy
Description: Given Autologous anti-CD19/anti-CD20 CAR-expressing naive/memory T cells IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV
Study: NCT00585559

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NAC IV infusion at 0.5 gm hourly and APAP placebo
Description: N-acetylcysteine IV infusion at 0.5 gm hourly and acetaminophen placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: APAP 1 gm q6 hours, plus NAC IV infusion at 0.5 gm hourly
Description: Acetaminophen 1 gm every 6 hours, plus N-acetylcysteine IV infusion at 0.5 gm hourly

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: APAP 1.5 gm q6 hours, plus NAC IV infusion at 0.5 gm hourly
Description: Acetaminophen 1.5 gm every 6 hours, plus N-acetylcysteine IV infusion at 0.5 gm hourly
Study: NCT01927718

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: 100 mg by mouth daily for 28 days in a 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide continued by mouth at the previous dose of 5 mg daily for 21 days on a 28 day cycle, 5 mg daily for 28 days on a 28 day cycle, 10 mg daily for 28 days on a 28 day cycle, or 15 mg daily for 28 days on a 28 day cycle.
Study: NCT03885934

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevnar 13®
Description: Prevnar 13® 13-valent PCV containing 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) in each 0.5 mL IM administration.
Study: NCT01927718

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Questionnaire completion at screening, once a month for the first 6 months, then every other month while on study.
Study: NCT02714543

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: antioxidant
Description: Capsules SM Fibro (antioxidants) once daily for 3 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aloevera gel
Description: aloevera gel one scoop to be applied 3-4 times daily for 3 months
Study: NCT04007029

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Given IV
Study: NCT01716208

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofatumumab + Fresh Frozen Plasma
Study: NCT03027505

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ready to Use Therapeutic Food (RUTF)
Description: MUAC used as the primary admission and exit criteria for children with MUAC \<125mm and no medical complication.~Single treatment of RUTF for severe and moderate malnourished children and gradual reduction of doses according to the MUAC and the weight of the child during treatment. MUAC split into 3 categories:~* MUAC \<115 mm: 175 kcal /kg/day~* 115 \<MUAC \<120mm: 125kcal/kg/day~* 120 \<MUAC \<125mm: 75kcal/kg/day
Study: NCT01220141

Intervention type: DRUG
Intervention: activated recombinant human factor VII
Description: Administration of room temperature stable NovoSeven® (activated recombinant human factor VII) in dosages prescribed by the treating physician according to the product labelling text approved in his country.
Study: NCT04288362

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention Group
Description: Participants in this arm will undergo the new care model for management of diabetes mellitus polyclinics.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: Participants in this arm will continue to undergo the existing care model for management of diabetes mellitus in the polyclinics.
Study: NCT01558674

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-7145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-7145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-7145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-7145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-7145

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Furosemide
Study: NCT04560231

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remdesivir
Description: 200 mg I/v Remdesivir will be given to moderate disease patients of COVID-19. It will be loading dose then 100 mg I/V dose will be given for 5 days. Customized decision for Remdesivir dosage will be made by attending infectious diseases physician, comfort with usage, bacterial co-infection and duration of Ventilation and dose will be extended up to 10 days according to clinical condition of the patients.
Study: NCT01685762

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: 850 mg of metformin taken once daily by mouth for 4 weeks (weeks 1-4) and then twice daily by mouth for 8 weeks (weeks 5-12).
Study: NCT01558674

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Furosemide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Torsemide
Study: NCT03797248

Intervention type: COMBINATION_PRODUCT
Intervention: Chinese herbal medicine
Description: All Chinese herbal products prescribed from TCM physicians in our hospital during patients receiving adjuvant chemotherapy

Intervention type: COMBINATION_PRODUCT
Intervention: Chinese herbal medicine
Description: All Chinese herbal products prescribed from TCM physicians in our hospital during patients receiving adjuvant chemotherapy
Study: NCT01746550

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MD-12-001 Stent
Description: MD-12-001 is a self-expanding nitinol stent
Study: NCT02544737

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Patients with metastatic lesions of esophageal cancer after been treated with surgery or definitive chemoradiotherapy receiving Apatinib (850mg) daily over 4 weeks.
Study: NCT01013532

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilostazol
Description: Cilostazol 100mg bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilostazol
Description: Cilostazol 100mg bid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Probucol
Description: Probucol 250mg bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probucol
Description: Probucol 250mg bid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Aspirin 100mg qd

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Aspirin 100mg qd

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo of cilostazol
Description: same shape and size of active cilostazol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo of cilostazol
Description: same shape and size of active cilostazol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo of aspirin
Description: same size and shape of active aspirin 100mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo of aspirin
Description: same size and shape of active aspirin 100mg
Study: NCT00441935

Intervention type: DEVICE
Intervention: Interstim Neuromodulation
Description: Two stage procedure to implant an interstim device for neuromodulation.
Study: NCT02425176

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum toxin A (BoNT-A) 50U
Description: Drug intervention:~The total dose is divided equally and injected into 4 salivary glands (submandibular and parotid gland bilaterally) via a 25G or 23G needle with ultrasound guidance. One site is injected per gland.~Drug is only injected once at baseline
Study: NCT01013532

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ankle-brachial index (ABI)
Description: measurement of ABI every years during follow up

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ankle-brachial index (ABI)
Description: measurement of ABI every years during follow up

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ankle-brachial index (ABI)
Description: measurement of ABI every years during follow up

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ankle-brachial index (ABI)
Description: measurement of ABI every years during follow up

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: intima-medial thickness (IMT)
Description: ultrasound measured IMT of both common carotid arteries
Study: NCT00819169

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AMG 479
Description: AMG 479 is an investigational, fully human, monoclonal antibody that binds with Insulin-like growth factor receptor type 1.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AMG 479
Description: AMG 479 is an investigational, fully human, monoclonal antibody that binds with Insulin-like growth factor receptor type 1.
Study: NCT01013532

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: intima-medial thickness (IMT)
Description: ultrasound measured IMT of both common carotid arteries

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intima-medial thickness (IMT)
Description: ultrasound measured IMT of both common carotid arteries

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intima-medial thickness (IMT)
Description: ultrasound measured IMT of both common carotid arteries

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: new asymptomatic brain hemorrhage
Description: asymptomatic macrobleedings or microbleedings on GRE images

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: new asymptomatic brain hemorrhage
Description: asymptomatic macrobleedings or microbleedings on GRE images
Study: NCT00819169

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AMG 479
Description: AMG 479 is an investigational, fully human, monoclonal antibody that binds with Insulin-like growth factor receptor type 1.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AMG 479
Description: AMG 479 is an investigational, fully human, monoclonal antibody that binds with Insulin-like growth factor receptor type 1.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AMG 655
Description: AMG 655 is an investigational, fully human, monoclonal antibody that binds with TNF-related apoptosis-inducing ligand, DR 5.
Study: NCT01013532

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: new asymptomatic brain hemorrhage
Description: asymptomatic macrobleedings or microbleedings on GRE images

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: new asymptomatic brain hemorrhage
Description: asymptomatic macrobleedings or microbleedings on GRE images

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: new ischemic lesions on follow-up FLAIR images
Description: any new ischemic lesions

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: new ischemic lesions on follow-up FLAIR images
Description: any new ischemic lesions
Study: NCT02425176

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum toxin A (BoNT-A) 100U
Description: The total dose is divided equally and injected into 4 salivary glands (submandibular and parotid gland bilaterally) via a 25G or 23G needle with ultrasound guidance. One site is injected per gland.
Study: NCT01013532

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: new ischemic lesions on follow-up FLAIR images
Description: any new ischemic lesions
Study: NCT00819169

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AMG 655
Description: AMG 655 is an investigational, fully human, monoclonal antibody that binds with TNF-related apoptosis-inducing ligand, DR 5.
Study: NCT02425176

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum toxin A (BoNT-A) 200U
Description: The total dose is divided equally and injected into 4 salivary glands (submandibular and parotid gland bilaterally) via a 25G or 23G needle with ultrasound guidance. One site is injected per gland.
Study: NCT04227340

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Photobiomodulation Therapy (PBM)
Description: The PBM will be delivered through application of the LED Cluster Probe externally to the right external buccal, left external buccal, mid face with mouth open and submandibular and left/right cervical. Patients who develop an oral lesion, intra-oral directed therapy will be administered with the dental light probe. For patients that can tolerate, an intraoral probe will deliver light directly onto the oral mucosa, this will then replace the mid face application with mouth open. Each laser application will be timed at 60 seconds.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain and Oral Function Assessment
Description: After the 6-minute laser/ treatment session the child and parent will complete the mucositis evaluation scale on paper or ipad which includes self-report oral function specific to ability to swallow, eat and drink, as well as the patient's self-reported need for medication specific to mouth pain.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Parent-Reported Satisfaction Survey
Description: A parent-reported satisfaction survey will be administered via paper questionnaire after the initial LLLT treatment. Parent satisfaction will be reported by parents on a 5-point Likert scale to questions adapted from a parent satisfaction survey used in a study regarding child life services in pediatric imaging.
Study: NCT00974103

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise advise
Description: Exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: chiropractic treatment and exercises
Description: Manipulation, mobilisation, soft tissue work, ergonomic and exercise advise. Maximum 12 treatments
Study: NCT03962452

Intervention type: GENETIC
Group type: OTHER
Intervention: Next Generation Sequencing (NGS)
Description: Determining the nucleic acid sequence